Boiron SA
PAR:BOI
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
28.1
42.4
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Boiron SA
Accounts Receivables
Boiron SA
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Boiron SA
PAR:BOI
|
Accounts Receivables
€77.7m
|
CAGR 3-Years
5%
|
CAGR 5-Years
2%
|
CAGR 10-Years
0%
|
||
Sanofi SA
PAR:SAN
|
Accounts Receivables
€8.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Ipsen SA
PAR:IPN
|
Accounts Receivables
€719.2m
|
CAGR 3-Years
9%
|
CAGR 5-Years
6%
|
CAGR 10-Years
10%
|
||
Vetoquinol SA
PAR:VETO
|
Accounts Receivables
€93.1m
|
CAGR 3-Years
0%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
||
Virbac SA
PAR:VIRP
|
Accounts Receivables
€222.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Medincell SA
PAR:MEDCL
|
Accounts Receivables
€1.5m
|
CAGR 3-Years
26%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
Boiron SA
Glance View
Boiron SA engages in the manufacturing and selling homeopathic medicines. The company is headquartered in Rontalon, Auvergne-Rhone-Alpes. The firm develops, manufactures and markets single homeopathic medicines and drugs which are in the form of tablets, syrups, single-dose liquids and ointments. The company also produces medicines based on trace elements, phytotherapy remedies, food supplements, as well as health and beauty care products. In addition, the Company owns a research center, which works for the development of homeopathy within the world of medicine. Boiron SA operates through a number of subsidiaries, which are based in Italy, Spain, Belgium, the Czech Republic, Slovakia, Russia, Romania, Poland, Hungary, the United States, Canada and Brazil, among others.
See Also
What is Boiron SA's Accounts Receivables?
Accounts Receivables
77.7m
EUR
Based on the financial report for Jun 30, 2024, Boiron SA's Accounts Receivables amounts to 77.7m EUR.
What is Boiron SA's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
0%
Over the last year, the Accounts Receivables growth was 0%. The average annual Accounts Receivables growth rates for Boiron SA have been 5% over the past three years , 2% over the past five years .